HSPA5 and cancer: To test the universality of this finding, we thus set out to evaluate the relative sensitivity of two types of GRP78-overexpressing subclones (Mahlavu and Hep J5) and SK-Hep-1 (Grp78-nonexpressing subclone) cells toward a group of ROS-producing anti-cancer drugs including doxorubicin, 5-fluorouracil and sorafenib.